Electra Therapeutics, Inc. (ETRA)
NASDAQ: ETRA · Real-Time Price · USD
11.82
-0.85 (-6.71%)
Sep 24, 2026, 4:00 PM EDT - Market closed
Company Description
Electra Therapeutics, Inc. is a clinical-stage biotechnology company.
It develops therapies that target signal regulatory proteins for the treatment of novel targets for diseases in immunology and cancer.
Its product, ELA026, is a monoclonal antibody that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, enabling medical professionals to find an approved treatment for secondary hemophagocytic lymphohistiocytosis, a life-threatening hyperinflammatory condition.
The company was incorporated in 2018 and is based in South San Francisco, California.
Electra Therapeutics, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Sep 18, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Quehuong Dong |
Contact Details
Address: 230 E Grand Avenue, Suite S-100 South San Francisco, California 94080 United States | |
| Phone | (888) 743-2290 |
| Website | electra-therapeutics.com |
Stock Details
| Ticker Symbol | ETRA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 2088082 |
| CUSIP Number | 284825106 |
| ISIN Number | US2848251060 |
| Employer ID | 83-2193635 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Quehuong (Kathy) Dong, Pharm.D., M.B.A. | President, Chief Executive Officer, Director |
| Chris Clark, C.F.A. | Chief Financial Officer |
| Kim-Hien Dao, D.O., Ph.D. | Chief Medical Officer |
| Gary S. Koe, Ph.D. | Chief Technical Officer |
| Graham Parry, Ph.D. | Chief Scientific Officer |
| Nancy Stagliano, Ph.D. | Chairperson |
| Matthew Fust, M.B.A. | Director |
| Thomas Geninatti, Ph.D. | Director |
| Carl L. Gordon, Ph.D., C.F.A. | Director |
| Beth Seidenberg, M.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 21, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Sep 21, 2026 | 8-K | Current Report |
| Sep 18, 2026 | 424B4 | Prospectus |
| Sep 18, 2026 | CERT | Certification by an exchange approving securities for listing |
| Sep 18, 2026 | 8-A12B | Registration of securities |
| Sep 17, 2026 | EFFECT | Notice of Effectiveness |
| Sep 17, 2026 | S-1MEF | Registration adding securities to prior Form S-1 registration |
| Sep 14, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Aug 28, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Aug 10, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |